Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

Research and Innovation Action · Running

ACT-CHIK Accelerating Clinical Trials for CHIKungunya Vaccine in Africa

Coordinator
Institut Pasteur, France
Runs
1 May 2026 to 30 April 2030
Status
Running
EU funding
€15.3m
Total cost
€15.9m
Partners
8 organisations in 7 countries
Type
Research and Innovation Action
Grant agreement
101249063

What the project is doing

In the project's own words, from its summary on CORDIS.

The Measles-virus chikungunya (MV-CHIK) vaccine is a live-attenuated, recombinant, measles-vectored vaccine developed from the Schwarz vaccine strain of the measles virus (MV) by the Institut Pasteur in Paris. The immunogenicity and protective efficacy of MVCHIK have been substantiated through studies conducted on a mouse model susceptible to the measles virus and in non-human primates, specifically adult cynomolgus macaques.

This evidence indicates that the neutralising antibodies elicited by the vaccine, with a titer of 5 x 10^5 ± 0.5 log TCID50, confer protection against lethal challenges posed by chikungunya and related diseases. Six Phase I and II clinical trials have been conducted, positioning the product for progression to further clinical assessments, with Phase 3 clinical trial material. In these preliminary safety, dose-finding, and immunogenicity investigations, 639 subjects received varied doses of the candidate vaccine across both endemic and non-endemic regions, and the results indicate satisfactory safety, tolerability, and immunogenicity profiles.

Derived from encouraging preclinical and Phase I–II clinical data, this grant proposal advocates for theclinical evaluation of the MV-CHIK candidate vaccine through a Phase Ib/III study involving adults, adolescents, and children residing in both non-endemic and endemic African countries to confirm the satisfactory safety and immunogenicity profiles of the MV-CHIK vaccine. The consortium will facilitate the generation of evidence-based clinical data and introduce an innovative MV vaccine platform to Africa for enhanced pandemic preparedness and outbreak control.

Comprehensive due diligence and gap analysis will be executed to pinpoint a manufacturing partner before implementing the technology transfer plan. The prospective impact of this vaccine on public health is considerable, offering a promising solution in the battle against chikungunya and associated diseases in Africa.

Topics

Who is involved

OrganisationCityCountryRole
Institut PasteurParisFranceCoordinator
Fiotec-Fundacao Para O Desenvolvimento Cientifico E Tecnologico Em SaudeRio De JaneiroBrazilThird party
Fundacao Oswaldo CruzRio De JaneiroBrazilParticipant
Kenya Medical Research InstituteNairobiKenyaParticipant
International Vaccine InstituteSeoulSouth KoreaParticipant
Irrua Specialist Teaching Hospital Board of ManagementIrruaNGParticipant
University of RwandaKigaliRWParticipant
Institut Pasteur De DakarDakarSNParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI